GH Research/GHRS

$8.72

8.59%
-
1D1W1MYTD1YMAX

About GH Research

GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.

Ticker

GHRS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Theis Terwey

Employees

32

Headquarters

Dublin, Ireland

Website

-

GH Research Metrics

BasicAdvanced
$417.73M
Market cap
-
P/E ratio
-$0.79
EPS
-
Beta
-
Dividend rate

What the Analysts think about GH Research

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
295.64% upside
High $50.00
Low $18.00
$8.72
Current price
$34.50
Average price target

GH Research Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-5.6M
-27.27%
Profit margin
0%
-

GH Research Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 44.78%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.32
-$0.21
-$0.15
-$0.11
-
Expected
-$0.17
-$0.22
-$0.25
-$0.20
-$0.20
Surprise
89.51%
-2.78%
-40.81%
-44.78%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell GH Research stock

Buy or sell GH Research stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing